Creative BioMolecules Inc. (CBMI), Enzon Inc. (ENZN) deal

The companies finalized their agreement to cross-license ENZN's Single-Chain Antigen-Binding (SCA) protein technology and CBMI's Biosynthetic Antibody Binding Site (BABS) protein technology. The non-exclusive, royalty-free license entitles the companies to develop and sell products using each other's patented technologies.

Each party also would be free to market products covered in the agreement in collaboration with third parties, who would be required to pay royalties to both ENZN and CMBI. ...